Syntab Therapeutics GmbH

Founding year

2010

Sector

Life Sciences / Biotechnology

Description

Development of immuno-oncology drugs that activate the innate immune system

The company develops cancer therapies in the preclinical area. In the future, the first active substances are also to be clinically developed at an early stage and subsequently licensed out to Big Pharma or Big Biotech.

The technology platform of the ISErs (innate immune system engagers) enables the ongoing generation of new product candidates, therefore the development pipeline is continuously filled.

Until the first licensing money is generated, the company acquires funding for its research & development, e.g. from the federal government, the state or the EU.

"An exciting project with great minds and brilliant cooperation partners. Together we are making an incredible amount possible."

Ute Steinbusch, Managing Director